5

10

15

20

## What is claimed is:


- 1. A polynucleotide molecule encoding an immunoglobulin, said polynucleotide molecule comprising (1) a first promoter and a first cistron forming a first promoter-cistron pair and (2) a second promoter and a second cistron forming a second promoter-cistron pair, wherein the first cistron of said first promoter-cistron pair comprises a first translational initiation region (TIR-L) operably linked to a nucleic acid sequence encoding an immunoglobulin light chain and the second cistron of said second promoter-cistron pair comprises a second translational initiation region (TIR-H) operably linked to a nucleic acid sequence encoding an immunoglobulin heavy chain, wherein upon expression of said polynucleotide in a prokaryotic host cell, the light and heavy chains are folded and assembled to form a biologically active immunoglobulin.
  - 2. The polynucleotide molecule of claim 1, wherein the first and second promoters are prokaryotic promoters selected from the group consisting of phoA, tac, lpp, lac-lpp, lac, ara, trp, trc and T7 promoters.
  - 3. The polynucleotide molecule of claim 2, wherein both promoters are PhoA promoters.
  - 4. The polynucleotide molecule of claim 1, wherein each of the TIR-L and TIR-H comprises a prokaryotic secretion signal sequence or variant thereof.
  - 5. The polynucleotide molecule of claim 4, wherein the prokaryotic secretion signal sequence is selected from the group consisting of STII, OmpA, PhoE, LamB, MBP and PhoA secretion signal sequences.
  - 6. The polynucleotide molecule of claim 1, wherein the TIR-L and TIR-H provide approximately equal translational strengths.
- 7. The polynucleotide molecule of claim 6, wherein the relative translational strength combination is about (1-TIR-L, 1-TIR-H).
  - 8. A recombinant vector for expressing an immunoglobulin in a prokaryotic host cell, said vector comprising the polynucleotide molecule of claim 1.
  - 9. A prokaryotic host cell comprising the recombinant vector of claim 8.

15

20

25


5



- 11. The host cell of claim 10 which is *E. coli*.
- 12. The host cell of claim 11, further comprising a polynucleotide encoding at least one prokaryotic polypeptide selected from the group consisting of DsbA, DsbC, DsbG and FkpA.
- 13. The host cell of claim 12, wherein the polynucleotide encodes both DsbA and DsbC.
- 14. The host cell of claim 11, wherein the *E. coli* is of a strain deficient in endogenous protease activities.
- 15. The host cell of claim 14, wherein the genotype of the *E. coli* strain lacks *degP* and *prc* genes and harbors a mutant *spr* gene.
  - 16. A process for producing a biologically active immunoglobulin in a prokaryotic host cell, said process comprising expressing in the host cell a polynucleotide comprising (1) a first promoter and a first cistron forming a first promoter-cistron pair and (2) a second promoter and a second cistron forming a second promoter-cistron pair, wherein the first cistron of said first promoter-cistron pair comprises a first translational initiation region (TIR-L) operably linked to a nucleic acid sequence encoding an immunoglobulin light chain and the second cistron of said second promoter-cistron pair comprises a second translational initiation region (TIR-H) operably linked to a nucleic acid sequence encoding an immunoglobulin heavy chain, wherein upon expression of said polynucleotide, said light chain and heavy chain are folded and assembled to form a biologically active immunoglobulin; and recovering said immunoglobulin.
  - 17. The process of claim 16, wherein the first and the second promoters are prokaryotic promoters selected from the group consisting of phoA, tac, lpp, lac-lpp, lac, ara, trp, trc and T7 promoters.
  - 18. The process of claim 17, wherein both the first and the second promoters are PhoA promoters.

5

- 19. The process of claim 16, wherein each of the TIR-L and TIR-H comprises a prokaryotic secretion signal sequence or variant thereof.
- 20. The process of claim 19, wherein the prokaryotic secretion signal sequence is selected from the group consisting of STII, OmpA, PhoE, LamB, MBP and PhoA secretion signal sequences.
- 21. The process of claim 16, wherein the TIR-L and TIR-H provide approximately equal translational strengths.
- 22. The process of claim 21, wherein the relative translational strength combination is about (1-TIR-L, 1-TIR-H).
- 10 23. The process of claim 16, wherein the prokaryotic host cell is *E. coli*.
  - 24. The process of claim 16, further comprising expressing in the prokaryotic host cell a polynucleotide encoding at least one prokaryotic polypeptide selected from the group consisting of DsbA, DsbC, DsbG and FkpA.
  - 25. The process of claim 24, wherein the polynucleotide encodes both DsbA and DsbC.
- 15 26. The process of claim 23, wherein the *E. coli* is of a strain deficient in endogenous protease activities.
  - 27. The process of claim 26, wherein the genotype of the *E. coli* lacks *degP* and *prc* genes and harbors a mutant *spr* gene.
  - 28. An aglycosylated full length antibody produced by a process according to claim 16.
- 29. The aglycosylated full length antibody of claim 28, wherein the immunoglobulin is a multispecific antibody.
  - 30. The aglycosylated full length antibody of claim 28, which is a non-human antibody.
  - 31. The aglycosylated full length antibody of claim 30, wherein the non-human antibody is humanized.
- The aglycosylated full length antibody of claim 28, which is a human antibody.



- 34. The immunoconjugate of claim 33, wherein the cytotoxic agent is selected from the group consisting of a radioactive isotope, a chemotherapeutic agent and a toxin.
- 5 35. The immunoconjugate of claim 34, wherein the toxin is selected from the group consisting of calichemicin, maytansine and trichothene.
  - 36. A composition comprising the aglycosylated full length antibody of claim 28 and a carrier.
  - 37. The composition of claim 36, wherein the carrier is pharmaceutically acceptable.
- 10 38. A composition comprising the immunoconjugate of claim 33 and a carrier.
  - 39. The composition of claim 38, wherein the carrier is pharmaceutically acceptable.
  - 40. An article of manufacture comprising a) a container and a composition contained therein, wherein the composition comprises an aglycosylated full length antibody of claim 28; and b) instruction for using said composition.
- 15 41. An article of manufacture comprising a) a container and a composition contained therein, wherein the composition comprises an immunoconjugate according to claim 33; and b) instruction for using said composition.